William F. Pierce - Concepedia

Author

William F. Pierce

Center for Drug Evaluation and Research ORCID

Also Known As

W.F. Pierce V, William F Pierce, William F. Pierce, William Pierce

Publications

2.4K

Citations

H-Index

Concepts

All Affiliations

Center for Drug Evaluation and Research United States Food and Drug Administration Center for Devices and Radiological Health United States Department of Health and Human Services

About

William F. Pierce is an author at Center for Drug Evaluation and Research specializing in pharmacotherapy, cancer therapeutics, and cancer research.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	5	5	649
2	Health Sciences	3	3	354
3	Diagnostic Sciences	2	2	311
4	Public Health	1	1	95
5	Environmental Health	1	1	95

William F. Pierce

Publications

2.2K

Citations

H-Index

Page 1

	Year	Citations
FDA Approval Summary: Lutetium Lu 177 Vipivotide Tetraxetan for Patients with Metastatic Castration-Resistant Prostate Cancer Jaleh Fallah, Sundeep Agrawal, Haley Gittleman, Clinical Cancer Research UrologyDry MouthGenitourinary CancerFda ReviewMedicine	2022	200
FDA Approval Summary: Atezolizumab Plus Bevacizumab for the Treatment of Patients with Advanced Unresectable or Metastatic Hepatocellular Carcinoma Sandra J. Casak, Martha Donoghue, Lola A. Fashoyin‐Aje, Clinical Cancer Research	2020	170
FDA Approval Summary: Pembrolizumab for the First-line Treatment of Patients with MSI-H/dMMR Advanced Unresectable or Metastatic Colorectal Carcinoma Sandra J. Casak, Leigh Marcus, Lola A. Fashoyin‐Aje, Clinical Cancer Research	2021	167
Radium Ra 223 Dichloride Injection: U.S. Food and Drug Administration Drug Approval Summary Paul G. Kluetz, William F. Pierce, V. Ellen Maher, Clinical Cancer Research Dichloride InjectionCancer ManagementPharmacotherapyOsteoporosisOrthopaedic Surgery	2013	162
FDA Approval Summary: Rucaparib for the Treatment of Patients with Deleterious <i>BRCA</i> Mutation–Associated Advanced Ovarian Cancer Sanjeeve Balasubramaniam, Julia A. Beaver, Sara Horton, Clinical Cancer Research	2017	158
FDA Approval Summary: Fam-Trastuzumab Deruxtecan-Nxki for the Treatment of Unresectable or Metastatic HER2-Positive Breast Cancer Preeti Narayan, Christy Osgood, Harpreet Singh, Clinical Cancer Research	2021	155
FDA Approval Summary: Belzutifan for von Hippel-Lindau Disease–Associated Tumors Jaleh Fallah, Michael H. Brave, Chana Weinstock, Clinical Cancer Research Surgical OncologyRenal PathologyPathologyPharmacotherapyNeuro-oncology	2022	149
FDA Approval Summary: Niraparib for the Maintenance Treatment of Patients with Recurrent Ovarian Cancer in Response to Platinum-Based Chemotherapy Gwynn Ison, Lynn Howie, Laleh Amiri‐Kordestani, Clinical Cancer Research	2018	125
FDA Approval: Ribociclib for the Treatment of Postmenopausal Women with Hormone Receptor–Positive, HER2-Negative Advanced or Metastatic Breast Cancer Anand Shah, Erik Bloomquist, Shenghui Tang, Clinical Cancer Research	2018	106
U.S. Food and Drug Administration Approval: Neratinib for the Extended Adjuvant Treatment of Early-Stage HER2-Positive Breast Cancer Harpreet Singh, Amanda J. Walker, Laleh Amiri‐Kordestani, Clinical Cancer Research	2018	96

Page 1